Skip to contentpdufa.bio

FDA Complete Response Letters: facts from the release

Page updated ·next FDA decision on the calendar ·Data as of Nov 21, 2026 10:10 PM ET

The FDA has released 466 records under its CRL transparency program (openFDA, last updated 2026-11-18; snapshot read 2026-11-21). 1 of them repeats another record (same date, application numbers and text), leaving 465 distinct records. 452 are Complete Response Letters dated 2009 to 2026. Each count below says which files it comes from and how it is made, so anyone can redo it. Counts and date differences only: no approval rates, no predictions. Every letter, by year; every CRL, by company.

Letters in the release, by year

Letter yearComplete Response Letters
202639
202560
202467
202330
202225
202146
202036
201936
201832
201724
201620
20159
20147
201312
20123
20112
20102
20092

The release also holds 5 records typed with no letter type; 4 records typed Tentative Approval; 1 record typed Refusal To File; 1 record typed Corrected Provisional Determination; 1 record typed Provisional Determination; 1 record typed Rescind Complete Response. They are not counted as CRLs on this page.

What the 2024+ letters name as deficient

165 Complete Response Letters dated 2024 or later have a PDF of their own. 163 of them have a text layer we read; 94 carry at least one deficiency section heading in the FDA's own words (labeling, safety update and other administrative sections set aside). The other 69 carry no deficiency heading that the extractor recognizes yet, so they are left out of the table rather than guessed; they are read again as its vocabulary grows. A letter can name several sections.

Section family (the letter's own heading)Letters, of 94
Product quality or CMC52
Facility inspections32
Clinical or statistical22
Clinical pharmacology11
Nonclinical11
Human factors or device8
Microbiology (heading as written, not further specified)10
REMS5

Headings are read from the PDF text layer only (extract_crl_headings.py), never from openFDA's OCR text.

Applications with more than one released CRL

81 applications (an original NDA or BLA, or one supplement) have two or more Complete Response Letters in the release; 24 have three or more. Grouped on the application number the FDA printed on each record; 2 letters the FDA later rescinded as issued in error are left out.

ApplicationCompanyLettersLetter dates
NDA 210852Dr. Reddy’s Laboratories Limited6July 24, 2018, May 3, 2019, November 20, 2019, May 21, 2020, November 6, 2020, April 18, 2022
NDA 206610Mylan Laboratories Limited5February 27, 2015, March 10, 2016, February 1, 2017, December 6, 2017, June 6, 2019
NDA 206968InnoPharma Licensing LLC4February 27, 2015, November 15, 2016, November 9, 2018, December 22, 2020
BLA 761082Kashiv BioSciences, LLC4May 10, 2018, June 11, 2019, December 22, 2020, August 2, 2021
NDA 022517Ferring Pharmaceuticals Inc.3April 22, 2010, January 30, 2013, January 30, 2015
NDA 206185Sun Pharma Advanced Research Company Lim3November 24, 2014, July 30, 2015, December 19, 2016
NDA 204417Sun Pharma Advanced Research Company Lim3March 29, 2013, September 23, 2015, March 22, 2017
NDA 204017Agile Therapeutics, Inc.3February 13, 2013, July 17, 2013, December 21, 2017
NDA 210735AuroMedics Pharma LLC3April 26, 2018, January 15, 2019, October 1, 2019
NDA 208574Teva Pharmaceuticals USA Inc.3June 1, 2016, June 2, 2017, November 4, 2019
NDA 205394IntelGenx Corp.3January 31, 2014, March 28, 2019, March 24, 2020
NDA 204957B. Braun Medical, Inc.3September 28, 2017, March 27, 2019, April 24, 2020
NDA 211413HQ Specialty Pharma Corporation3October 19, 2018, December 26, 2019, January 8, 2021
NDA 210274Zhejiang Novus Pharmaceuticals Co. Ltd.3June 15, 2018, November 27, 2020, August 25, 2021
NDA 210136Braeburn Inc.3January 19, 2018, December 1, 2020, December 15, 2021

The 66 others are on the full list.

From the last released CRL to approval (NDAs)

For 167 original NDAs, the FDA's Orange Book (products file, FDA files dated 2026-11-13) lists a first approval after the last Complete Response Letter in the release (rescinded letters left out). Days from that letter to that approval: median 423, middle half (quartiles) 298 to 680, shortest 49, longest 3623.

Letter to approvalNDAs
under 1 year63
1 to 2 years71
2 to 3 years13
3 years or more20

Read this as a description of the released letters, not of CRLs in general: the FDA released its older letters for applications it had approved, and recent letters have had little time to resolve. BLAs are not in the Orange Book and are not counted. 3 NDAs whose earliest listed product predates the letter are left out. Shortest gaps:

NDAProduct (Orange Book)Last CRLApprovedDays
211321NayzilamMarch 29, 2019May 17, 201949
219122BrynovinNovember 4, 2024January 16, 202573
211241ZycuboSeptember 30, 2025January 12, 2026104
210821Tetracaine HydrochlorideNovember 20, 2018March 12, 2019112
211970Vyondys 53August 19, 2019December 12, 2019115

Labeled "Unapproved" by openFDA, approved in the Orange Book

openFDA's approval_status field says these 11 letters belong to applications not approved. The Orange Book lists each NDA as approved after the letter. Both are FDA files; the Orange Book lists each product as approved, and each approval it lists is dated before openFDA's last update (2026-11-18).

NDAProductCRLOrange Book approval
218592PixclaraApril 25, 2025September 11, 2026
217379CavhanzaJune 14, 2024May 29, 2026
211241ZycuboSeptember 30, 2025January 12, 2026
217338Mucinex 12Hr Cold & Fever Multi-SympJuly 26, 2024December 22, 2025
218571CardamystMarch 27, 2025December 12, 2025
212271ContepoDecember 11, 2024October 22, 2025
217294Lasix OnyuJanuary 12, 2024October 7, 2025
215029BondlidoJuly 11, 2024September 24, 2025
215244ForzinityMay 15, 2025September 19, 2025
218879SubveniteJanuary 3, 2025September 16, 2025
218698LopressorJune 12, 2024August 28, 2025

Letters the FDA rescinded

NDA 202408, Fera Pharmaceuticals, LLC: a record typed "Rescind Complete Response" dated March 28, 2019 (PDF). It is not counted as a CRL above. It names the FDA's earlier letters on the application as issued in error; those letters stay in the yearly count, because they are in the release, and are left out of the repeat-CRL and letter-to-approval counts.

The letter's date against our decision page's date

31 decision pages on this site carry the FDA's own released letter. Days from the letter's date (the FDA's stated action date, for a corrected letter) to the date our decision page is filed under:

Days after the letterPages
05
115
25
34
4 or more2

Four days or more: CING-2026-06-02 (4 days after the letter of May 29, 2026); RARE-2025-07-11 (4 days after the letter of July 7, 2025).

How this page is made

Inputs: the FDA's CRL release (openFDA transparency/crl, snapshot 2026-11-21), the section headings each PDF's text layer carries (_crl_headings.json), the Orange Book products file (_orange_book/products.txt), and this site's decision pages. The script is build_crl_facts.py in the site's public repository; it runs on every rebuild. A letter the FDA released twice (same date, application numbers and text) is counted once. Capricor's two CRLs for deramiocel, from the primary sources.